Combination of Novel Therapies for CKD Comorbid Depression

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 201 participants.

Also called NCT04422652

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 201 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04422652
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04422652. Randomized; quadruple masking; primary purpose treatment. Start 2020-09-24 (actual); primary completion 2026-09-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Combination of Novel Therapies for CKD Comorbid Depression
Acronym
CONCORD
Condition
Chronic Kidney Diseases
Condition
Major Depressive Disorder
Condition
End Stage Kidney Disease (ESRD)
Intervention (Drug)
Bupropion
Intervention (Behavioral)
Behavioral activation therapy
Intervention (Drug)
Placebo
Intervention (Other)
Clinical Management
Lead sponsor
Stony Brook University (class: other)
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct04422652
Content hash
f1543ede7a13af90f490853c12ac4328c8408f2b0cc06bd19e64470a5ea113a4